Drug intelligence / Profile preview

vebreltinib + temozolomide

Development stage: Phase 2
Lead developer: Apollomics
Modality: Small Molecules
Administration: Oral

Overview

Vebreltinib + temozolomide is an investigational combination therapy being studied for the treatment of glioblastoma, particularly in patients with IDH-mutant or secondary glioblastoma harboring PTPRZ1-MET fusion gene positivity. Vebreltinib (also known as PLB1001 or APL-101) is a small molecule inhibitor targeting the MET proto-oncogene receptor tyrosine kinase (MET), which plays a role in tumor growth and survival. Temozolomide is an oral alkylating agent that induces DNA damage leading to apoptosis in cancer cells. The combination aims to leverage targeted inhibition of MET-driven signaling alongside cytotoxic chemotherapy to improve outcomes in aggressive brain tumors[1][2][3][7].

Other names: bozitinib + temozolomide

Targets

DNAMET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on vebreltinib + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vebreltinib + temozolomide.